Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
Deutsche Version Deutsche Version
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Krebsforschung_EN.png
 
 
 
Hauptnavigation
  • Home
  • General Information
    • History
    • 50 years Institute for Cancer Research
    • Imagevideo: Institute for Cancer Research
  • Research
    • Research Focus
    • Research Laboratories
    • Scientific Services - Core Facilities
  • Teaching
    • Lectures of the Institute of Cancer Research
    • University Course Toxicology for Postgraduates
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Program Malignant Diseases
    • PhD Program Clinical and Experimental Oncology
  • Contact
    • Contact
    • Map
 
Research / Research Focus / Tumor Progression and Metastasis / Wolfgang Mikulits
 
Subnavigation
  • Research Focus
    • Cellular and Molecular Tumorbiology
    • Applied and Experimental Oncology
    • Chemical Safety and Cancer Prevention
    • Tumor Progression and Metastasis
      • Wolfgang Mikulits
        • Research Projects
        • Group Members
      • Iros Barozzi
  • Research Laboratories
  • Scientific Services - Core Facilities


Inhaltsbereich

 

Wolfgang Mikulits, Ao.Univ.-Prof. Mag. Dr.
Coordinator of Research Focus "Tumor Progression and Metastasis"
Group Leader
E-Mail: wolfgang.mikulits [at] meduniwien [dot] ac [dot] at
Phone:  +43 (0)1 40160 - 57527
Fax:  +43 (0)1 40160 - 957519

Research Focus

The spread of cells from the primary cancer to distant organs is the most fearsome aspect of cancer. This process of cancer progression denoted as metastasis has exceptional clinical relevance and represents the major reason for the death of cancer patients. Upon the progression of carcinoma, changes in cell plasticity by the epithelial to mesenchymal transition (EMT) are of particular significance for local cell invasion, immune cell interactions, entry into vessels and chemoresistance. We focus on the molecular mechanisms underlying the EMT of hepatocellular carcinoma (HCC) which is the major subtype of aggressive liver cancer. The use of hypothesis-driven EMT models translated into pre-clinical and clinical settings allow the identification and functional characterization of promising EMT regulatory molecules amenable to diagnostic/prognostic assessment and therapeutic Intervention.

Financial support:

Austrian Science Fund (FWF) doc.funds program DOC 59-B33, FWF P31720, FWF P25356, FWF P20905, FWF T597-B13, FWF P19598, SFB F2806, FWF 15435, EU-FP7 HEALTH-F4-2008-202047, EU-FP7-PEOPLE-2012-ITN “IT-LIVER” Nr. 316549, Oesterreichische Nationalbank - Anniversary Fund, Herzfelder’sche Family Foundation, Hochschuljubiläumsfonds der Stadt Wien, OEAD Austria - Czech Republic, OEAD Austria - Spain.

Group Members

Group Members

Videos

Selected Publications

Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma.
Haider C, Hnat J, Wagner R, Huber H, Timelthaler G, Grubinger M, Coulouarn C, Schreiner W, Schlangen K, Sieghart W, Peck-Radosavljevic M, Mikulits W.
Hepatology. 2019 Jan;69(1):222-236. doi: 10.1002/hep.30166

Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics.
Holstein E, Binder M, Mikulits W.
Int J Mol Sci. 2018 Dec 18;19(12). pii: E4111. doi.org/10.3390/ijms19124111

Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis.
Dengler M, Staufer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stift J, Brostjan C, Gruenberger T, Kumada T, Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W.
Oncotarget. 2017 Jul 11;8(28):46234-46248. doi: 10.18632/oncotarget.17598

Role of epithelial to mesenchymal transition in hepatocellular carcinoma.
Giannelli G, Koudelkova P, Dituri F, Mikulits W.
J Hepatol. 2016 Oct;65(4):798-808. doi: 10.1016/j.jhep.2016.05.007

Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma.
Reichl P, Dengler M, van Zijl F, Huber H, Führlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M, Mikulits W.
Hepatology. 2015 Mar;61(3):930-41. doi: 10.1002/hep.27492

 

 

All Publications

PubmedDatabase

 
Print
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact